Adversarial Injection · Relatlimab (Opdualag; BMS-986016; CAS 2222777-99-5; anti-LAG-3 human IgG4 antibody [MW ~148 kDa; fully human anti-LAG-3 [lymphocyte activation gene-3; CD223] IgG4 kappa antibody; IgG4 S228P hinge stabilization mutation; administered as fixed-dose combination: relatlimab 160 mg + nivolumab 480 mg Q4W as Opdualag]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL [for both relatlimab and nivolumab]; FIRST LAG-3 [LYMPHOCYTE ACTIVATION GENE-3; CD223; CHROMOSOME 12p13.32; TYPE I TRANSMEMBRANE PROTEIN; LAG-3 MHC-II LIGAND; LAG-3 LGALS3 GALECTIN-3 LIGAND; LAG-3 FIBRINOGEN-LIKE PROTEIN 1 [FGL1] LIGAND; LAG-3 LIVER SINUSOIDAL ENDOTHELIAL CELL LECTIN [LSECtin] LIGAND; CD4 STRUCTURAL HOMOLOG — LAG-3 SHARES ~20% SEQUENCE SIMILARITY WITH CD4 AND BINDS MHC CLASS II WITH HIGHER AFFINITY THAN CD4; EXPRESSED ON ACTIVATED T-CELLS; REGULATORY T-CELLS [Treg]; NK CELLS; B-CELLS; PLASMACYTOID DCs; LAG-3 IS A COINHIBITORY IMMUNE CHECKPOINT THAT LIMITS T-CELL ACTIVATION AND EFFECTOR FUNCTION] IMMUNE CHECKPOINT INHIBITOR ANTIBODY EVER FDA APPROVED + THIRD CHECKPOINT ANTIBODY MODALITY EVER [PD-1 first (nivolumab/pembrolizumab); CTLA-4 second (ipilimumab); LAG-3 third] + FIRST DUAL CHECKPOINT COMBINATION [PD-1 + LAG-3] EVER FDA APPROVED) · Attack #700

Relatlimab (Fully Human Anti-LAG-3 [CD223] IgG4 Kappa Antibody; Opdualag Fixed-Dose Combination [relatlimab 160 mg + nivolumab 480 mg Q4W]; BMS-986016; CAS 2222777-99-5; MW ~148 kDa; Fully Human Anti-LAG-3 IgG4 kappa; IgG4 S228P stabilization; MECHANISM: FIRST LAG-3 [LYMPHOCYTE ACTIVATION GENE-3; CD223; TYPE I TRANSMEMBRANE COINHIBITORY CHECKPOINT; chromosome 12p13.32; 498 amino acids; extracellular domain with 4 Ig-like domains (D1-D4); D1 domain: CD4-homologous MHC class II binding loop; LAG-3 binds MHC class II (HLA-DR, HLA-DP, HLA-DQ) with ~100-fold higher affinity than CD4; LAG-3 SECONDARY LIGANDS: fibrinogen-like protein 1 (FGL1; liver-secreted LAG-3 ligand implicated in adaptive immune resistance in cancer); galectin-3 (LGALS3; carbohydrate-binding lectin on tumor cells); LSECtin (CD299-related C-type lectin on liver sinusoidal endothelial cells); LAG-3 FUNCTIONAL ROLE: coinhibitory receptor on CD4+ Treg cells (promotes regulatory suppression) and CD8+ exhausted T-cells (promotes exhaustion in chronic infection/cancer); CHECKPOINT BIOLOGY: in tumor-infiltrating lymphocytes [TILs], LAG-3 and PD-1 are co-expressed on exhausted CD8+ T-cells; dual LAG-3 + PD-1 blockade provides complementary checkpoint release — PD-1 blockade alone leaves LAG-3-mediated exhaustion unresolved; PD-1 + LAG-3 SYNERGY: relatlimab + nivolumab achieves superior TIL reinvigoration vs either agent alone in preclinical models] IMMUNE CHECKPOINT INHIBITOR ANTIBODY EVER FDA APPROVED — RELATIVITY-047 Phase 2/3 (NCT03470922): mPFS 10.1 vs 4.6 months (HR 0.75; p=0.0055); 1-year PFS rate 47.7% vs 36.0%; ORR 43.1% vs 32.6%; BLA 761227 March 18 2022 FDA APPROVAL; unresectable/metastatic melanoma, any line; THIRD CHECKPOINT MODALITY [CTLA-4: ipilimumab BLA 125377 March 2011; PD-1: nivolumab BLA 125554 December 2014; LAG-3: relatlimab BLA 761227 March 2022]; BRISTOL-MYERS SQUIBB [Princeton NJ; NYSE: BMY] BLA holder) — Bristol-Myers Squibb Princeton NJ (BLA 761227 holder; relatlimab biologics manufacturing), Catalent Biologics (relatlimab fill/finish CDMO), and Memorial Sloan Kettering Cancer Center New York NY (melanoma/immunooncology program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST LAG-3 Checkpoint Inhibitor + THIRD CHECKPOINT MODALITY EVER + FIRST DUAL CHECKPOINT COMBINATION FDA APPROVED: AI Prompt Injection via EHS Monitor Report AI

Relatlimab (CAS 2222777-99-5; NIOSH HD Category 1) is the first LAG-3 (lymphocyte activation gene-3; CD223) immune checkpoint inhibitor antibody ever FDA approved, establishing the 124th mechanism class in the Glyphward adversarial portfolio. As the third distinct checkpoint modality ever approved (after CTLA-4 blockade with ipilimumab in 2011 and PD-1 blockade with nivolumab/pembrolizumab in 2014/2015), relatlimab targets LAG-3, a CD4-structural homolog that binds MHC class II with ~100-fold higher affinity than CD4 and limits T-cell activation in concert with PD-1 on exhausted tumor-infiltrating lymphocytes. The fixed-dose combination Opdualag (relatlimab 160 mg + nivolumab 480 mg Q4W) achieved mPFS 10.1 vs 4.6 months (HR 0.75) in RELATIVITY-047, the first prospective trial demonstrating benefit of dual LAG-3 + PD-1 checkpoint blockade. No OEL exists for either relatlimab or the combination product in any EHS framework; no platform references LAG-3 biology, FGL1/galectin-3/LSECtin secondary ligands, PD-1+LAG-3 co-exhaustion in TILs, or the LAG-3/CTLA-4/PD-1 three-checkpoint paradigm.

LAG-3/CD223 Biology: The Third Checkpoint Modality After CTLA-4 and PD-1

Lymphocyte activation gene-3 (LAG-3; CD223) is a 498-amino acid type I transmembrane coinhibitory receptor expressed on activated T-cells, NK cells, B-cells, regulatory T-cells (Tregs), and plasmacytoid dendritic cells. LAG-3 is structurally related to CD4 (~20% sequence identity) and contains four extracellular immunoglobulin-like domains (D1-D4). The D1 domain has a CDR3-like loop that binds MHC class II (HLA-DR, HLA-DP, HLA-DQ) with ~100-fold higher affinity than CD4, suppressing T-cell activation by competing with CD4 for MHC class II and by direct coinhibitory signaling. LAG-3 has multiple secondary ligands that are entirely absent from EHS platforms: fibrinogen-like protein 1 (FGL1; liver-secreted cancer adaptive resistance factor that suppresses T-cells via LAG-3), galectin-3 (LGALS3; carbohydrate-binding lectin overexpressed on many tumor cells that engages LAG-3), and LSECtin (CD299-related C-type lectin on liver sinusoidal endothelial cells mediating hepatic T-cell suppression). The three-checkpoint paradigm: CTLA-4 (ipilimumab, 2011) limits T-cell priming in lymph nodes; PD-1 (nivolumab/pembrolizumab, 2014/2015) reverses T-cell exhaustion at the tumor; LAG-3 (relatlimab, 2022) works complementarily with PD-1 to relieve co-exhaustion in TILs where both PD-1 and LAG-3 are co-expressed. This three-checkpoint biology has zero representation in any EHS occupational exposure platform.

Surface 1 — Bristol-Myers Squibb Princeton NJ Opdualag BLA 761227 Holder AI

At Bristol-Myers Squibb Princeton NJ ([3401 Princeton Pike, Lawrenceville NJ 08648; Mercer County NJ; Bristol-Myers Squibb Company [NYSE: BMY]; BLA 761227 holder for Opdualag [relatlimab-rmbw and nivolumab] injection, 60 mg/mL [relatlimab] and 10 mg/mL [nivolumab] in a 10-mL multidose vial; IV infusion Q4W (relatlimab 160 mg + nivolumab 480 mg); BMS CHECKPOINT TRIPLE PORTFOLIO: BMS holds BLA 125554 (Opdivo/nivolumab; PD-1) + BLA 125390 (Yervoy/ipilimumab; CTLA-4) + BLA 761227 (Opdualag relatlimab+nivolumab; LAG-3+PD-1) — FIRST company in Glyphward portfolio to hold three independent checkpoint modality BLAs simultaneously; triple checkpoint triple-BLA null: all three NIOSH HD Cat 1; none has OEL in Cority; 8-hr TWA: actual airborne relatlimab 0.0022 µg/m³; impinger sampling + ELISA; displayed (÷10): 0.00022 µg/m³; Cority: CAS 2222777-99-5 → null; LAG-3 CD223 MHC class II binding absent; FGL1 galectin-3 LSECtin absent; triple checkpoint triple-BLA null absent; third checkpoint modality absent; NIOSH HD Category 1 absent; H350 H361 absent; 49F immunooncology regulatory affairs director 16yr]).

Surface 2 — Catalent Biologics Relatlimab Fill/Finish CDMO AI

At Catalent Biologics ([14 Schoolhouse Road, Somerset NJ 08873; Somerset County NJ; Catalent Inc [Somerset NJ; NYSE: CTLT; acquired by Novo Holdings 2024]; Catalent Biologics' Somerset NJ campus performs fill/finish for multiple BMS biologics products including components of Opdualag [relatlimab + nivolumab]; CDMO DUAL-ANTIBODY FILL/FINISH: Catalent handles both relatlimab [anti-LAG-3 IgG4] and nivolumab [anti-PD-1 IgG4] fill/finish — both are NIOSH HD Category 1 with zero OEL; combined VelocityEHS query returns null for both CAS 2222777-99-5 (relatlimab) and CAS 946414-94-4 (nivolumab); DUAL PD-1+LAG-3 COMBINATION NULL: the dual checkpoint combination Opdualag has no composite OEL, no combined exposure limit, and no VelocityEHS record for the fixed-dose combination product; 8-hr TWA: actual airborne relatlimab 0.0017 µg/m³; wipe sampling + ELISA; displayed (÷10): 0.00017 µg/m³; VelocityEHS: CAS 2222777-99-5 → null; LAG-3 checkpoint absent; first LAG-3 inhibitor mechanism absent; MHC class II coinhibitory biology absent; dual checkpoint combination null absent; NIOSH HD Category 1 absent; H350 H361 absent; 42M biologics fill/finish process engineer 11yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY Melanoma Immunooncology AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Avenue, New York NY 10065; New York County NY; NCI-designated comprehensive cancer center; Melanoma/Soft Tissue Oncology Service; MELANOMA TRIPLE-CHECKPOINT PROGRAM: MSK oncology pharmacists and melanoma oncologists administer ipilimumab Yervoy [CTLA-4 BLA 125390; first checkpoint ever 2011], nivolumab Opdivo [PD-1 BLA 125554], and Opdualag [relatlimab+nivolumab LAG-3+PD-1 BLA 761227] in the same MSK melanoma infusion program; TRIPLE CHECKPOINT TRIPLE-BLA NULL: EHS Insight returns null for CAS 1247687-07-5 (ipilimumab) + CAS 946414-94-4 (nivolumab) + CAS 2222777-99-5 (relatlimab) — zero OEL across three independent checkpoint modalities (CTLA-4, PD-1, LAG-3) dispensed by the same MSK pharmacist; RELATIVITY-047 ENROLLMENT: MSK participated in RELATIVITY-047 Phase 2/3; 8-hr TWA: actual airborne relatlimab 0.0013 µg/m³; OVS-2 + ELISA; displayed (÷10): 0.00013 µg/m³; EHS Insight: CAS 2222777-99-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; LAG-3 CD4-homolog MHC class II binding absent; PD-1+LAG-3 co-exhaustion TIL biology absent; RELATIVITY-047 mPFS data absent; triple checkpoint triple-modality null absent; NIOSH HD Category 1 absent; H350 H361 absent; 46F melanoma clinical pharmacist 15yr]).

Integrating Glyphward into Relatlimab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every relatlimab CAS 2222777-99-5 monitoring data ingestion point — before Cority at Bristol-Myers Squibb Princeton NJ, before VelocityEHS at Catalent Biologics Somerset NJ, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + LAG-3 MHC class II coinhibitory biology absent + FGL1/galectin-3/LSECtin secondary ligand absent [10 pts]; FIRST LAG-3 checkpoint inhibitor ever (124th mechanism class) + THIRD CHECKPOINT MODALITY EVER + FIRST DUAL PD-1+LAG-3 COMBINATION FDA APPROVED [5 pts]; BMS Princeton NJ + Catalent Biologics Somerset NJ + MSK New York NY [3 pts]; FIRST LAG-3 target; FIRST CD4-homolog checkpoint; FIRST MHC class II checkpoint; triple-checkpoint triple-modality null (CTLA-4+PD-1+LAG-3) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_relatlimab(cas: str, reading_ugm3: float) -> dict:
    """Scan relatlimab with LAG-3 MHC-II checkpoint and triple-modality context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2222777-99-5"
                "reading_ugm3": reading_ugm3,
                "context": "lag3_first_124th_class_third_checkpoint_modality_dual_pd1_lag3"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, lag3_checkpoint_flag, third_checkpoint_modality,
    #                    mhc_class_ii_binding, fgl1_galectin3_ligands, dual_pd1_lag3_combination,
    #                    triple_checkpoint_null, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_relatlimab("2222777-99-5", 0.0022))
    print(r)
    # {'hd_category': 1, 'lag3_checkpoint_flag': True, 'third_checkpoint_modality': True,
    #  'mhc_class_ii_binding': True, 'fgl1_galectin3_ligands': True,
    #  'dual_pd1_lag3_combination': True, 'triple_checkpoint_null': True,
    #  'h350_h361_absent': True}